drugset / Trial / NCT07252739
KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)
RandomizedParallel-groupSingle-blindTreatment
Summary
Researchers want to learn if using a study medicine called MK-1084 can help treat Non-Small Cell Lung Cancer (NSCLC). MK-1084 is a type of treatment called targeted therapy for the Kirsten rat sarcoma viral oncogene homolog (KRAS) G12C gene change. The goal of this study is to learn about the safety of MK-1084 and to learn how many people have the cancer get smaller or go away during the study treatment.
Timeline
- Start
- 2025-12-19
- Primary completion
- 2029-11-15
- Completion
- 2032-05-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Calderasib | Unknown | — | Oral |
| Subject | Cetuximab | Monoclonal antibody | 500 mg/m2 | Intravenous |
| Subject | Sacituzumab Tirumotecan | Other / unclassified | 4 mg/kg | Intravenous |
| Background | Acetaminophen | Small molecule | — | — |
| Background | Dexamethasone | Small molecule | — | — |
| Background | Diphenhydramine | Small molecule | — | — |
| Background | Pembrolizumab | Monoclonal antibody | 400 mg | Intravenous |